Clinical trials: Eosinophilic Enteritis
Eosinophilic Esophagitis
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
This trial will study three doses of reslizumab versus placebo in children with eosinophilic esophagitis (EE). The objectives of the trial will be to study the effectiveness of reslizumab in improving the clinical signs and…
- Trial name
- NCT00538434
- Testing
- Reslizumab, Saline
- Where
- 37 sites in United States, Canada
- Volunteers
- 227 people
- Sponsor
- Ception Therapeutics
Eosinophilic Esophagitis
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
A Phase 1b/2 study to explore the safety, efficacy and pharmacokinetics of EP-104GI in adults with eosinophilic esophagitis (EoE).
- Trial name
- RESOLVE (NCT05608681)
- Testing
- EP-104GI, Matching vehicle control
- Where
- 23 sites in Australia, Canada and 4 more
- Volunteers
- 117 people
- Sponsor
- Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538.
- Trial name
- NCT04991935
- Testing
- CC-93538
- Where
- 167 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Celgene
Eosinophilic Esophagitis (EoE)
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding…
- Trial name
- EoE-TOTs (NCT07112378)
- Testing
- dupilumab
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Regeneron Pharmaceuticals
Eosinophilic Esophagitis
24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (EoE) followed by a single-arm, open-label extension.
- Trial name
- NCT05634746
- Testing
- APT-1011, Esophagogastroduodenoscopy
- Where
- 60 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Eosinophilic Esophagitis
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult…
- Trial name
- CROSSING (NCT05583227)
- Testing
- Tezepelumab
- Where
- 124 sites in United States, Australia and 20 more
- Volunteers
- 368 people
- Sponsor
- AstraZeneca
Eosinophilic Esophagitis (EoE)
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
The principal aim of this study is to obtain safety and tolerability data when AQ280 is administered orally as single and multiple doses to healthy subjects.
- Trial name
- NCT05485779
- Testing
- AQ280
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- AQILION AB
Eosinophilic Esophagitis (EoE)
Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis
This is a randomized, placebo-controlled, parallel-arm, dose-ranging study in subjects with eosinophilic esophagitis, 2-18 years of age. Eligible subjects will be randomized into one of four treatment groups.
- Trial name
- NCT00762073
- Testing
- budesonide
- Where
- 20 sites in United States
- Volunteers
- 82 people
- Sponsor
- Shire
Eosinophilic Gastritis, Eosinophilic Duodenitis
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacodynamic effect of subcutaneous lirentelimab (AK002), given monthly for 6 doses, in…
- Trial name
- ENIGMA-SC (NCT05152563)
- Testing
- AK002
- Where
- 76 sites in United States
- Sponsor
- Allakos Inc.
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)
This is a 3-part study. Part A is randomized, double-blinded, placebo-controlled and includes patients with eosinophilic gastritis and/or duodenal-only disease.
- Trial name
- HUDSON GI (NCT05251909)
- Testing
- Benralizumab
- Where
- 20 sites in United States, Brazil and 7 more
- Volunteers
- 12 people
- Sponsor
- AstraZeneca
Eosinophilic Esophagitis
Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
This study is an open-label study where all subjects will receive active drug, reslizumab. Subjects are able to enter this trial only through completion of study Res-05-0002 (NCT00538434).
- Trial name
- NCT00635089
- Testing
- reslizumab
- Where
- 36 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- Ception Therapeutics
Eosinophilic Esophagitis
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants…
- Trial name
- NCT04753697
- Testing
- CC-93538
- Where
- 212 sites in United States, Argentina and 13 more
- Volunteers
- 430 people
- Sponsor
- Celgene
Eosinophilic Esophagitis
A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021
This purpose of this study is the long-term follow-up of glucocorticosteroid-related adverse events and hypothalamic-pituitary-adrenal axis (HPA) suppression in subjects after discontinuation of study drug received in the PR-021…
- Trial name
- NCT01498497
- Testing
- EUR-1100
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Forest Laboratories
Eosinophilic Esophagitis (EoE)
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
- Trial name
- NCT06598462
- Testing
- Solrikitug Low Dose, Solrikitug Mid Dose, Solrikitug High Dose
- Where
- 73 sites in United States, Australia and 7 more
- Volunteers
- 184 people
- Sponsor
- Uniquity One (UNI)
Eosinophilic Esophagitis
A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
This is a longitudinal, observational non-interventional study (NIS) designed to characterize the patient population who receives dupilumab for eosinophilic esophagitis (EoE) treatment in a real-world setting in Germany with…
- Trial name
- ProMEAL (NCT06695897)
- Testing
- Dupilumab
- Where
- 15 sites in Germany
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi
Eosinophilic Esophagitis
Mesalazine Oral Suspension in Active Eosinophilic Esophagitis
Pilot study to assess a mesalazine oral suspension in active eosinophilic esophagitis
- Trial name
- NCT05488405
- Testing
- Mesalamine Oral Product
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- Dr. Falk Pharma GmbH
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
This is a Phase 2, double-blind, randomized, placebo-controlled study to assess the effects of AK002, given monthly for 4 doses.
- Trial name
- ENIGMA (NCT03496571)
- Testing
- AK002
- Where
- 21 sites in United States
- Volunteers
- 65 people
- Sponsor
- Allakos Inc.
Eosinophilic Oesophagitis
A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5…
- Trial name
- NCT06101095
- Testing
- Dupilumab
- Where
- 30 sites in United States, Brazil and 3 more
- Volunteers
- 69 people
- Sponsor
- Sanofi
Eosinophilic Esophagitis
A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic Esophagitis
This is a randomized, placebo-controlled, double-blind trial to evaluate the efficacy, tolerability, and safety of ESO-101 in adult patients with active eosinophilic esophagitis (EoE).
- Trial name
- NCT04849390
- Testing
- ESO-101
- Where
- 17 sites in Germany, Netherlands and 3 more
- Volunteers
- 43 people
- Sponsor
- EsoCap AG
Eosinophilic Esophagitis (EoE)
Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302 extension study.
- Trial name
- NCT03245840
- Testing
- Budesonide oral suspension
- Where
- 45 sites in United States
- Volunteers
- 133 people
- Sponsor
- Shire